What to Do When Initial Digoxin Immune Fab Fails in Life-Threatening Digoxin Toxicity with Cardiac Arrest
Clinical Scenario
This protocol applies to a patient in cardiac arrest with life-threatening signs of digoxin toxicity — specifically one or more of the following: ventricular tachycardia or fibrillation, asystole or symptomatic high-degree atrioventricular block, severe hyperkalaemia (serum potassium >6.5 mmol/L), or hypotension (systolic blood pressure <100 mmHg) associated with end-organ dysfunction.
- Ventricular tachyarrhythmia / fibrillation
- Asystole / high-degree AV block
- Serum K&sup+; >6.5 mmol/L
- sBP <100 mmHg + end-organ dysfunction
- Cardiac arrest
Previous Treatment & Failure Condition
An initial course of digoxin immune Fab was administered immediately on recognition of life-threatening toxicity in cardiac arrest.
Adequate clinical response was not achieved: the expected normalisation of serum potassium concentration, body temperature, blood pressure, ECG, and renal function did not occur within the response window. This failure to reach those goals triggers escalation to the next step.
Next-Line Approach (Partial Overview)
The escalation step involves administering an additional course of digoxin immune Fab. The specific quantity, timing, and full monitoring requirements are detailed in the complete structured protocol.
Full regimen details — including sequencing and monitoring parameters — are available via the protocol below.
Monitoring Goals
Following administration, close monitoring is required until normalisation of serum potassium concentration, body temperature, blood pressure, ECG, and renal function (serum urea, creatinine, and estimated glomerular filtration rate).
References
DOI: 10.1097/MEJ.0000000000001065
- Ventricular tachycardia or fibrillation
- Asystole or symptomatic, high-degree atrioventricular block
- Severe hyperkalaemia (serum potassium >6.5 mmol/L)
- Hypotension (systolic blood pressure <100 mmHg) associated with end-organ dysfunction
- The consensus expert opinion was that for patients with digoxin toxicity in cardiac arrest (loss of cardiac output due to asystole, pulseless electrical activity or tachyarrhythmias), five vials of digoxin immune Fab (40 milligrams per vial) are administered immediately.
- For patients with potentially life-threatening digoxin toxicity who are in cardiac arrest, five vials (or as many vials as available up to a maximum of five) of digoxin immune Fab (40 milligrams per vial) should be administered immediately; if an adequate clinical response is not seen after 30 min, a further five vials can be given.
- Patients should be monitored closely after administration of digoxin immune Fab, including assessment of serum potassium concentrations, body temperature, blood pressure, ECG and renal function (serum urea and creatinine and estimated glomerular filtration rate); monitoring should continue until potassium concentration, ECG and renal function are 'normalised'.
View source ↗